Mesoblast Limited
MESO
$11.60
-$0.22-1.86%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -39.71% | -39.92% | -37.47% | -28.77% | -2.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.71% | -39.92% | -37.47% | -28.77% | -2.72% |
| Cost of Revenue | -69.70% | -63.73% | -56.73% | -50.49% | -28.67% |
| Gross Profit | 76.67% | 68.15% | 59.82% | 53.98% | 32.83% |
| SG&A Expenses | -2.17% | -13.54% | -25.66% | -27.48% | -12.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 101.63% | 95.26% | 88.10% | 89.29% | -2,237.85% |
| Total Operating Expenses | -31.95% | -33.26% | -31.40% | -27.45% | -19.40% |
| Operating Income | 30.97% | 32.47% | 30.71% | 27.30% | 21.10% |
| Income Before Tax | -12.34% | 4.44% | 12.51% | 17.89% | 13.06% |
| Income Tax Expenses | 152.56% | 86.61% | 25.97% | 30.93% | 12.69% |
| Earnings from Continuing Operations | -12.76% | 4.23% | 12.47% | 17.85% | 13.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.76% | 4.23% | 12.47% | 17.85% | 13.06% |
| EBIT | 30.97% | 32.47% | 30.71% | 27.30% | 21.10% |
| EBITDA | 31.03% | 32.43% | 30.45% | 26.94% | 21.27% |
| EPS Basic | 17.66% | 28.34% | 33.33% | 38.97% | 28.25% |
| Normalized Basic EPS | 31.59% | 40.15% | 45.72% | 45.96% | 30.15% |
| EPS Diluted | 17.73% | 28.40% | 33.38% | 39.01% | 28.18% |
| Normalized Diluted EPS | 31.59% | 40.15% | 45.72% | 45.96% | 30.15% |
| Average Basic Shares Outstanding | 8.71% | 4.94% | 2.91% | 6.27% | 21.97% |
| Average Diluted Shares Outstanding | 8.71% | 4.94% | 2.91% | 6.27% | 21.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
